The present study showed that only 9 per cent of patients with cancer had elevated serum CEA levels, and low AUC and sensitivity, with the distribution of serum CEA being similar in patients with cancer and benign disease (Fig. 1). This evidence concerns the gene CEACAM5 and cancer.